Latest Array Biopharma Inc (ARRY) Headlines
Price Movements, Clinical Trial Results, and Solid Financial Reports - Analyst Notes on Pfizer, Dendreon, DepoMed, Globus Medical, and Array
PR Newswire - Wed Mar 05, 12:13PM CST
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Dendreon Corp. (NASDAQ: DNDN), DepoMed Inc. (NASDAQ: DEPO), Globus Medical, Inc. (NYSE: GMED), and Array BioPharma, Inc. (NASDAQ: ARRY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380 in Combination with TDM-1 in Patients with Metastatic HER2+ Breast Cancer
PR Newswire - Thu Feb 20, 7:00AM CST
Oncothyreon Inc. (NASDAQ: ONTY) and Array BioPharma Inc. (NASDAQ: ARRY) today announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Kadcyla® (ado-trastuzumab emtansine or TDM-1) in patients with metastatic HER2+ breast cancer. ONT-380 is an orally active, reversible and selective small-molecule HER2 inhibitor invented by Array and being developed by Oncothyreon in collaboration with Array.
Oi S.A. - MATERIAL FACT: Consolidation of the Activities and Businesses of Oi and Portugal Telecom
PR Newswire - Thu Feb 20, 3:03AM CST
Oi S.A. ("Oi" or the "Company", Bovespa: OIBR3, OIBR4; NYSE: OIBR and OIBR.C) and Telemar Participacoes S.A. ("CorpCo"), in accordance with article 157, paragraph 4 of Law No. 6,404/76 (the "Brazilian Corporations Law") and CVM Instruction No. 358/02, notifies their shareholders and the market in general of the previously informed transaction of the combination, in one entity, of the activities and business operations of Oi in Brazil and Portugal Telecom, SGPS, S.A. ("Portugal Telecom") in Portugal and Africa, consolidating the industrial alliance between Oi and Portugal Telecom, initiated in 2010 and developed since that time, and combining the shareholder bases of Oi, Portugal Telecom and CorpCo (the "Transaction").
Array BioPharma To Present At The RBC Capital Markets Global Healthcare And Cowen Annual Healthcare Conferences
PR Newswire - Tue Feb 18, 11:45AM CST
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the RBC Capital Markets Global Healthcare and Cowen Annual Healthcare Conferences. The public is welcome to participate in the conferences through webcasts on the Array BioPharma website.
Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
PR Newswire - Thu Feb 06, 3:30PM CST
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Leerink Swann Healthcare Conference in New York. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
Why Array Biopharma Inc. Shares (Briefly) Popped
Alex Planes, The Motley Fool - Motley Fool - Tue Feb 04, 11:42AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Array Biopharma opened 10% higher this...
Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2014
PR Newswire - Tue Feb 04, 7:00AM CST
Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the second quarter of its fiscal year ending June 30, 2014.
Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380 in Combination with Capecitabine and/or Trastuzumab in Patients with Metastatic HER2+ Breast Cancer
PR Newswire - Mon Feb 03, 7:00AM CST
Oncothyreon Inc. (NASDAQ: ONTY) and Array BioPharma Inc. (NASDAQ: ARRY) today announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Xeloda® (capecitabine) and/or Herceptin® (trastuzumab) in patients with metastatic HER2+ breast cancer. ONT-380 is an orally active, reversible and selective small-molecule HER2 inhibitor invented by Array and being developed by Oncothyreon in collaboration with Array.
Brandywine Realty Trust Announces Tax Characteristics of Its 2013 Distributions
PR Newswire - Wed Jan 29, 3:30PM CST
Brandywine Realty Trust (NYSE: BDN) announced today the tax characteristics of its 2013 distributions. The tax reporting will be done on Form 1099-DIV and shareholders are encouraged to consult with their personal tax advisors as to the specific tax treatment of dividends. The characteristics of the Company's distributions are as follows:
Array BioPharma to Report Financial Results for the Second Quarter of Fiscal 2014 on February 4, 2014
PR Newswire - Wed Jan 29, 10:00AM CST
Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the second quarter of fiscal 2014 and hold a conference call to discuss those results on Tuesday, February 4, 2014. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.
Zacks #1 Rank Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 21, 8:30AM CST
Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List for Tuesday
Annual J.P. Morgan Healthcare Conference Presentations, Results of Self-Tender Offer, and Executive Appointment - Research Report on ICU Medical, Integra, Taro, AMAG, and Array BioPharma
PR Newswire - Fri Jan 10, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting ICU Medical, Inc. (NASDAQ: ICUI), Integra LifeSciences Holdings Corporation (NASDAQ: IART), Taro Pharmaceutical Industries Ltd. (NYSE: TARO), AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), and Array BioPharma Inc. (NASDAQ: ARRY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Array BioPharma To Present At The Annual J.P. Morgan Healthcare Conference
PR Newswire - Fri Jan 03, 12:30PM CST
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the Annual J.P. Morgan Healthcare Conference in San Francisco. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
Positive Trial Results, Completed Acquisitions, and Clearances - Research Report on Dyax, IPC, Array BioPharma, Lexicon Pharmaceuticals, and Wright Medical
PR Newswire - Fri Dec 20, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Global Encephalomyelitis Pipeline Review Report - H2 2013
M2 - Fri Dec 20, 6:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/svxp6q/encephalomyelitis) has announced the addition of the "Encephalomyelitis - Pipeline Review, H2 2013" report to their offering. 'Encephalomyelitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Encephalomyelitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Encephalomyelitis. Scope - A snapshot of the global therapeutic scenario for Encephalomyelitis. - A review of the Encephalomyelitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Encephalomyelitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Encephalomyelitis Therapeutics Development - Takeda Pharmaceutical Company Limited - Elan Corporation, plc - Hadasit Medical Research Services & Development Ltd - Compugen Ltd. - Array BioPharma Inc. - Resverlogix Corp. - KAHR medical Ltd. - Cognosci, Inc. - Encephalomyelitis - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Route of Administration - Assessment by Molecule Type Drug Profiles - IRX-5183 - KAHR-101 - KAHR-104 - COG-112 - Antiarrhythmic Drug - Phosphodiesterase Type 5 Inhibitors - Cholesterol Absorption Inhibitor - CGEN-15021 - CGEN-15091 - RVX-297 - AR-460770 - VCE-003 - VCE-004 - PP-090-45 - COG-133 - Thymulin - thymopentin - TAK-779 - Soluble Immune Response Suppressors - VLA-4 Antagonists - Activated Protein C For more information visit http://www.researchandmarkets.com/research/sv...lomyelitis
Early Morning Technical Insight:Johnson & Johnson, Mylan, Brookdale Senior Living, and Array BioPharma
PR Newswire - Tue Dec 17, 7:21AM CST
Editor Note: For more information about this release, please scroll to bottom.
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Dec 14, 7:15AM CST
With only a few weeks remaining in 2013, some stocks could be poised to go out with a bang -- while others go out with a thud. Count these three stocks in the latter category. Here are the past week's most horrendous health-care perfomers. Selling...
Reports, Positive Results, Updated Clinical Safety and Efficacy Data by Healthcare Companies - Research Report on Johnson & Johnson, Merck, BioMarin, Array BioPharma, and Brookdale Senior Living
PR Newswire - Thu Dec 12, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Array BioPharma, Inc. (NASDAQ: ARRY), and Brookdale Senior Living Inc. (NYSE: BKD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Why Array BioPharma, Genie Energy, and Hanwha SolarOne Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Dec 09, 7:31PM CST
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. In general, investors remained bullish today, sending the...
Nasdaq stocks posting largest percentage decreases
AP - Mon Dec 09, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Price Movements, Clinical Trial Results, and Solid Financial Reports - Analyst Notes on Pfizer, Dendreon, DepoMed, Globus Medical, and Array
PR Newswire - Wed Mar 05, 12:13PM CST
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Dendreon Corp. (NASDAQ: DNDN), DepoMed Inc. (NASDAQ: DEPO), Globus Medical, Inc. (NYSE: GMED), and Array BioPharma, Inc. (NASDAQ: ARRY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380 in Combination with TDM-1 in Patients with Metastatic HER2+ Breast Cancer
PR Newswire - Thu Feb 20, 7:00AM CST
Oncothyreon Inc. (NASDAQ: ONTY) and Array BioPharma Inc. (NASDAQ: ARRY) today announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Kadcyla® (ado-trastuzumab emtansine or TDM-1) in patients with metastatic HER2+ breast cancer. ONT-380 is an orally active, reversible and selective small-molecule HER2 inhibitor invented by Array and being developed by Oncothyreon in collaboration with Array.
Oi S.A. - MATERIAL FACT: Consolidation of the Activities and Businesses of Oi and Portugal Telecom
PR Newswire - Thu Feb 20, 3:03AM CST
Oi S.A. ("Oi" or the "Company", Bovespa: OIBR3, OIBR4; NYSE: OIBR and OIBR.C) and Telemar Participacoes S.A. ("CorpCo"), in accordance with article 157, paragraph 4 of Law No. 6,404/76 (the "Brazilian Corporations Law") and CVM Instruction No. 358/02, notifies their shareholders and the market in general of the previously informed transaction of the combination, in one entity, of the activities and business operations of Oi in Brazil and Portugal Telecom, SGPS, S.A. ("Portugal Telecom") in Portugal and Africa, consolidating the industrial alliance between Oi and Portugal Telecom, initiated in 2010 and developed since that time, and combining the shareholder bases of Oi, Portugal Telecom and CorpCo (the "Transaction").
Array BioPharma To Present At The RBC Capital Markets Global Healthcare And Cowen Annual Healthcare Conferences
PR Newswire - Tue Feb 18, 11:45AM CST
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the RBC Capital Markets Global Healthcare and Cowen Annual Healthcare Conferences. The public is welcome to participate in the conferences through webcasts on the Array BioPharma website.
Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
PR Newswire - Thu Feb 06, 3:30PM CST
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Leerink Swann Healthcare Conference in New York. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
Why Array Biopharma Inc. Shares (Briefly) Popped
Alex Planes, The Motley Fool - Motley Fool - Tue Feb 04, 11:42AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Array Biopharma opened 10% higher this...
Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2014
PR Newswire - Tue Feb 04, 7:00AM CST
Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the second quarter of its fiscal year ending June 30, 2014.
Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380 in Combination with Capecitabine and/or Trastuzumab in Patients with Metastatic HER2+ Breast Cancer
PR Newswire - Mon Feb 03, 7:00AM CST
Oncothyreon Inc. (NASDAQ: ONTY) and Array BioPharma Inc. (NASDAQ: ARRY) today announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Xeloda® (capecitabine) and/or Herceptin® (trastuzumab) in patients with metastatic HER2+ breast cancer. ONT-380 is an orally active, reversible and selective small-molecule HER2 inhibitor invented by Array and being developed by Oncothyreon in collaboration with Array.
Brandywine Realty Trust Announces Tax Characteristics of Its 2013 Distributions
PR Newswire - Wed Jan 29, 3:30PM CST
Brandywine Realty Trust (NYSE: BDN) announced today the tax characteristics of its 2013 distributions. The tax reporting will be done on Form 1099-DIV and shareholders are encouraged to consult with their personal tax advisors as to the specific tax treatment of dividends. The characteristics of the Company's distributions are as follows:
Array BioPharma to Report Financial Results for the Second Quarter of Fiscal 2014 on February 4, 2014
PR Newswire - Wed Jan 29, 10:00AM CST
Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the second quarter of fiscal 2014 and hold a conference call to discuss those results on Tuesday, February 4, 2014. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.
Zacks #1 Rank Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 21, 8:30AM CST
Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List for Tuesday
Annual J.P. Morgan Healthcare Conference Presentations, Results of Self-Tender Offer, and Executive Appointment - Research Report on ICU Medical, Integra, Taro, AMAG, and Array BioPharma
PR Newswire - Fri Jan 10, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting ICU Medical, Inc. (NASDAQ: ICUI), Integra LifeSciences Holdings Corporation (NASDAQ: IART), Taro Pharmaceutical Industries Ltd. (NYSE: TARO), AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), and Array BioPharma Inc. (NASDAQ: ARRY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Array BioPharma To Present At The Annual J.P. Morgan Healthcare Conference
PR Newswire - Fri Jan 03, 12:30PM CST
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the Annual J.P. Morgan Healthcare Conference in San Francisco. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
Positive Trial Results, Completed Acquisitions, and Clearances - Research Report on Dyax, IPC, Array BioPharma, Lexicon Pharmaceuticals, and Wright Medical
PR Newswire - Fri Dec 20, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Global Encephalomyelitis Pipeline Review Report - H2 2013
M2 - Fri Dec 20, 6:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/svxp6q/encephalomyelitis) has announced the addition of the "Encephalomyelitis - Pipeline Review, H2 2013" report to their offering. 'Encephalomyelitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Encephalomyelitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Encephalomyelitis. Scope - A snapshot of the global therapeutic scenario for Encephalomyelitis. - A review of the Encephalomyelitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Encephalomyelitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Encephalomyelitis Therapeutics Development - Takeda Pharmaceutical Company Limited - Elan Corporation, plc - Hadasit Medical Research Services & Development Ltd - Compugen Ltd. - Array BioPharma Inc. - Resverlogix Corp. - KAHR medical Ltd. - Cognosci, Inc. - Encephalomyelitis - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Route of Administration - Assessment by Molecule Type Drug Profiles - IRX-5183 - KAHR-101 - KAHR-104 - COG-112 - Antiarrhythmic Drug - Phosphodiesterase Type 5 Inhibitors - Cholesterol Absorption Inhibitor - CGEN-15021 - CGEN-15091 - RVX-297 - AR-460770 - VCE-003 - VCE-004 - PP-090-45 - COG-133 - Thymulin - thymopentin - TAK-779 - Soluble Immune Response Suppressors - VLA-4 Antagonists - Activated Protein C For more information visit http://www.researchandmarkets.com/research/sv...lomyelitis
Early Morning Technical Insight:Johnson & Johnson, Mylan, Brookdale Senior Living, and Array BioPharma
PR Newswire - Tue Dec 17, 7:21AM CST
Editor Note: For more information about this release, please scroll to bottom.
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Dec 14, 7:15AM CST
With only a few weeks remaining in 2013, some stocks could be poised to go out with a bang -- while others go out with a thud. Count these three stocks in the latter category. Here are the past week's most horrendous health-care perfomers. Selling...
Reports, Positive Results, Updated Clinical Safety and Efficacy Data by Healthcare Companies - Research Report on Johnson & Johnson, Merck, BioMarin, Array BioPharma, and Brookdale Senior Living
PR Newswire - Thu Dec 12, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Array BioPharma, Inc. (NASDAQ: ARRY), and Brookdale Senior Living Inc. (NYSE: BKD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Why Array BioPharma, Genie Energy, and Hanwha SolarOne Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Dec 09, 7:31PM CST
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. In general, investors remained bullish today, sending the...
Nasdaq stocks posting largest percentage decreases
AP - Mon Dec 09, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
